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Introduction
African trypanosomiasis, a parasitic infection caused by flagel-
lated extracellular parasites that survive in the tissue fluids and 
the bloodstream, encompasses a number of diseases affecting both 
humans and animals.
Most trypanosome species are unable to infect man and hence 
are in the first place a burden for the economic development of 
endemic areas. This feature of the disease is due to the presence 
of two trypanolytic factors in human serum (TLF1 and TLF2) 
that provide a level of innate resistance, preventing human infec-
tions.1,2 Trypanosoma congolense and Trypanosoma vivax and to a 
lesser extent Trypanosoma brucei brucei and Trypanosoma evansi are 
responsible for the animal disease Nagana, (or depressed spirits 
in the Zulu language) which causes estimated losses of over US 
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to date, human african trypanosomiasis (Hat) still threatens 
millions of people throughout sub-Sahara africa, and new 
approaches to disease prevention and treatment remain 
a priority. it is commonly accepted that Hat is fatal unless 
treatment is provided. However, despite the well-described 
general symptoms of disease progression during distinct 
stages of the infection, leading to encephalitic complications, 
coma and death, a substantial body of evidence has been 
reported suggesting that natural acquired immunity could 
occur. Hence, if under favorable conditions natural infections 
can lead to correct immune activation and immune protection 
against Hat, the development of an effective anti-Hat vaccine 
should remain a central goal in the fight against this disease.
in this review, we will (1) discuss the vaccine candidates that 
have been proposed over the past years, (2) highlight the main 
obstacles that an efficient anti-trypanosomiasis vaccine needs 
to overcome and (3) critically reflect on the validity of the wide-
ly used murine model for Hat.
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$1,300 million per year in resource-poor settings.3 All these para-
sites have a wide host range, which includes most economically 
important livestock species such as cattle and goat. Trypanosoma 
equiperdum is a disease that primarily affects horses, causing 
Dourine. Transmission of animal trypanosomiasis occurs mainly 
through its natural insect vector, the tsetste fly, but can also be 
accomplished through mechanical transmission by biting insects. 
The latter has allowed certain animal trypanosomes to propagate 
outside the African continent, as is the case for T. evansi and T. 
vivax that have become endemic to Asia and South America.4-6 
Sexual transmission of trypanosomiasis so far has only been con-
firmed in the case of T. equiperdum.7
HAT (or sleeping sickness) is caused by either Trypansoma 
brucei gambiense or Trypanosoma brucei rhodesiense, combined 
accounting for over 10,000 reported human infection cases a 
year.8 Both these parasites have developed resistance mechanisms 
that neutralize the function of the human trypanolytic serum fac-
tors TLF1 and TLF2.9-11 T. b. gambiense, commonly found in West 
and Central Africa, causes over 90% of the reported HAT cases. 
It evolves as a chronic disease characterized by a slow progres-
sion to the late/encephalitic stage and eventual death. In contrast,   
T. b. rhodesiense, present in East and Southern Africa, is respon-
sible for acute infections with a rapid onset and a faster progression 
of disease. All human infective trypanosomes are transmitted by 
the tsetse fly (Glossina sp) in a clearly defined region of Africa, the 
so-called tsetse belt.12 Important is that T. b. rhodesiense is primar-
ily a zoonotic disease, where disease outbreaks can be attributed 
to the continuous presence of a livestock reservoir of the human 
infective parasite.
Despite the significant amount of yearly HAT victims, disease 
prevalence is at historic low levels when compared with the infec-
tion incidence recorded over the past 100 years13 due to efficient 
control campaigns that have been initiated and maintained over 
the last decade. Despite these efforts, the reality is that HAT is 
still a neglected disease that requires further research on preven-
tion, diagnosis and treatment strategies. In particular now that the 
incidence has become low, detection of the remaining cases is cru-
cial to prevent re-emergence of the disease. In addition, tackling ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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space.24 Thus, competition for resources within the host, alle-
lopathic interference by excreted factors and immune-mediated 
competition might be at play. Important to note is that during 
human HAT surveillance, co-infections of T. brucei gambiense 
and the normally non-human infective T. congolense have been 
reported.25 Although this situation appears to occur only at very 
rare occasions, it is an interesting thought that regular exposure 
to T. congolense could provide human subjects with a certain 
level of protection against human pathogenic trypanosomes.
The genes that confer tolerance in cattle or human are not yet 
identified, though considerable effort is currently being made to 
clarify the location of the implicated genes. Studies performed on 
T. congolense infected mice have led to the identification of three 
quantitative trait loci (QTL), which are regions in the genome 
that have an influence on a quantitative trait or phenotype (i.e., 
body weight, anemia and parasitemia control). Three such 
regions named trypanosome infection response (Tir1, Tir2, Tir3) 
have been defined by Kemp et al.26 among which Tir1 showed 
the greatest effect on survival. Coincidentally, the tumor necrosis 
factorα (TNFα) gene is within a group of genes that co-localize 
to that particular locus, thus becoming an interesting candidate 
for resistance. As a matter of fact, TNFα has been reported to be 
a key mediator of host survival in experimental models,27 as well 
as intervening in parasite control.28,29 Two other crucial immuno-
regulatory genes that have an impact on infection outcome have 
been found to map close to Tir3b. These are the interleukin 10 
(IL-10) gene and a regulatory gene implicated in IL-10 synthe-
sis, Cypr2.30 Interestingly, IL-10 is implicated in the prevention 
of immunopathological lesions due to an exaggerated immune 
response.31 Upon T. congolense infection in particular, IL-10 acti-
vates a battery of genes involved in the control of inflammatory 
processes, thus preventing pathogenicity and promoting host 
resistance.32
With reference to human cases, clinical profiles of T. b. rhod-
esiense infected patients from several HAT foci have been subject 
of study in recent years.33-35 However, while no genetic loci have 
yet been identified for trypanotolerance, it has been hypothesized 
that the ethnical origin of the subject might influence the out-
come of the disease. People from Bantu origin, who have been 
exposed to trypanosomes for thousands of years, may thus be 
more resistant to infection. On the other hand, people of Nilotic 
ancestry, who are relatively new to the contact with trypano-
somes, are more susceptible. However, with only a few contra-
dictory reports on this subject available to date,20,36 no sound 
conclusion can be drawn as to one ethnicity being more resistant 
than the other.
Vaccine Candidates for HAT: Past and Present
As most mammals on the African continent are capable of deal-
ing with trypanosomes as well as with other parasites, and as 
even certain human infections apparently manifest themselves 
as long-lasting well-controlled infections, it should be taken 
into account that under optimal conditions even the human 
immune system can be instructed to mount a protective anti-
parasite response in case of exposure to trypanosomes. This, 
the zoonotic nature of East-African HAT, and hence dealing with 
the animal reservoir of in particular T. b. rhodesiense, should be a 
priority. Taken that full eradication of the parasite reservoir from 
the African livestock and game population is unfeasible, vacci-
nation against trypanosomiasis should be an integral part of the 
fight against HAT in infection endemic areas, as it is the only 
strategy that will provide protection against re-infection of the 
human population. In summary, the target locations would be in 
the first place areas where the animal reservoir represents a con-
stant danger for human populations, and in particular, areas such 
as northern Uganda, which is already endemic for T. b. gambiense 
infection.14 In the circumstance of merging, treatment provision 
would be dramatically delayed due to the uncertainty regarding 
the type of disease (acute or chronic infection). Last but not least, 
any endemic area in the tsetse belt with a relatively high transmis-
sion rate (for example the Democratic Republic of Congo) should 
be considered as candidate for vaccination programs.
African trypanosomiasis: A Natural Killer Disease by 
Default or an ill-Adapted Parasitic Infection  
for Certain Hosts?
Trypanotolerance is a trait that confers the capacity to survive 
and remain productive upon trypanosome infection.15 As dem-
onstrated by Naessens et al. trypanotolerance in cattle is a result 
of two independent mechanisms: (1) the capacity to control par-
asitemia, which is independent of the hematopoietic system and 
(2) the capacity to limit anemia, which is mediated by hemopoi-
etic cells. The latter appears to be more important for survival 
and productivity. With regards to trypanotolerance in human 
trypanosomiasis, several reports suggest indeed the existence 
of such phenomenon. For example, a study on trypanosome 
infected patients in Côte d’Ivoire reported that after refusing 
treatment, patients that had been diagnosed with HAT both 
by microscopy and serology were found to be parasitologically 
negative when re-examined 7 years later. While some individu-
als even became ‘sero-negative’ showing no anti-trypanosome 
antibody titers in their serum over time, others remained ‘sero-
positive’, even though parasites could not be detected in blood, 
thus considered asymptomatic carriers.17 Despite the general 
description of HAT as a ‘deadly disease’, asymptomatic carriers 
have been reported in the literature for both T. b. gambiense18,19 
and T. b. rhodesiense20,21 infections. Even though those differ-
ences in the outcome of the disease can be attributed to genetic 
variations in parasite virulence,22 it has been demonstrated 
in mouse models that the host genotype can play a crucially 
important role in severity of disease as well.23 Furthermore, it 
has been observed that co-infections of parasite strains can play 
a major role in attenuated disease progression,24 which could 
partially contribute to regional differences observed in HAT 
outcome. Indeed, as reported by Balmer et al.24 co-infections in 
murine models with both high and lower virulent trypanosome 
stocks lead to a strong mutual competitive suppression early in 
infection. The level of suppression is related to the density of 
the co-infecting strains, and it is believed to be the result of an 
active inhibition rather than a numerical response due to limited ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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a crucial role in bloodstream forms of T. brucei, not only due to 
its involvement in cell division, movement and morphology, but 
especially because it is indispensable for the formation of coated 
vesicles from the FP membrane.46 Li et al. published an immuni-
zation study using recombinant T. evansi actin, which shows high 
homology with T. equiperdum, T.b. brucei and T. cruzi. Actin-
immunized mice were protected to different extents according 
to the trypanosome species of challenge, and did not undergo 
autoimmune reactions.47 These results are supported by another 
study of Li et al. in which mice immunized with recombinant 
β-tubulin of T. evansi were protected from lethal challenge with 
T. evansi, T. equiperdum and T.b. brucei.48 It was suggested that 
this protection was antibody-mediated, and that these would 
reach their target by internalization through a yet to be discov-
ered mechanism. However, particular care should be taken with 
the interpretation of these results as the parasite challenge was 
only done 6 days after the third vaccine boost, using a relatively 
low parasite dose of 1,000 parasites. Hence the functional imple-
mentation of immunological memory was not addressed by this 
study, and moreover the authors did not provide a sound explana-
tion as to how antibodies could access their intracellular cytoskel-
eton protein target.
Similar to the vaccination approach by Li et al. anti-tubulin 
vaccination has been reported to result in partial protection against 
trypanosomiasis by Lubega et al.49 Here, tubulin was targeted as 
a major component within the cytoskeleton with involvement in 
various intracellular functions, including the maintenance of cel-
lular architecture, cell motility and transport.50 Tubulin immu-
nization of mice conferred sterile protection to 60–80% of the 
animals, including in heterologous challenges of T. brucei, T. con-
golense and T.b. rhodesiense.49 However, as in the case of the stud-
ies of Li et al. the short period between vaccination boosts and 
parasite challenge does not allow to draw any conclusion about 
the actual functional involvement of immunological memory in 
the observed results, and neither was a sound hypothesis provided 
as to how the presumed protective antibodies actually conferred 
their protective intracellular mode of action. Finally, neither the 
actin nor tubulin vaccine studies resulted in a follow-up study in 
a more realistic field setting.
Other membrane-associated candidates for vaccine develop-
ment that have been described are trypanosome trans-sialidases 
and cation pumps. Sialidases are membrane-associated enzymes 
that transfer sialic acid from sialylated glycoconjugates from the 
host’s cell surface to acceptor molecules on the parasite’s surface.51 
Though the enzyme has been thoroughly studied in T. cruzi, it 
has not yet been investigated in T. brucei. Immunization with a 
plasmid encoding the catalytic and N-terminal domain of the 
enzyme conferred 60% of protection in mice when challenged 
with a low dose of 500 T.b. brucei parasites,52 hence obtaining 
similar results as the FP-vaccination results outlined above. With 
respect to the immune targeting of parasite cation pumps, essen-
tial for survival and cation homeostasis of the parasite, vaccination 
was shown to provoke a biased stimulation of pro-inflammatory 
cytokines, though it failed to induce long-term protection.53
Taken the limited success of anti-trypanosome vaccinations 
described above, a number of research groups have taken an alter-
native approach in the past, and have addressed the possibility of 
together with the fact that eradication of the entire trypano-
some reservoir is unthinkable, suggests that anti-trypanosome 
vaccination has to be the ultimate target in the fight against 
HAT. However, thus far, the goal of obtaining an effective vac-
cine candidate with potential use in a realistic field setting has 
not been achieved.
Initially, vaccine trails against trypanosomiasis started target-
ing the surface coat of the parasite. This coat is composed by 10 
million copies of a single molecule: the variant surface glycopro-
tein (VSG). In principle, this surface protein would be an ideal 
vaccine candidate, if it were not for the antigenic variation strat-
egy that the parasites have cunningly evolved. Before the basis 
of the evasion mechanism was elucidated, the first vaccination 
strategies focused on the abundant VSG molecules as targets.37 
Soon however, it became obvious that such an approach would 
never succeed due to (1) the innumerable possible molecules that 
the parasite can generate through gene rearrangements and (2) 
the fact that the main immunoglobulin response that they elicit 
is that of the IgM isotype, which is short lived.
Yet, while undergoing antigenic variation, trypanosomes 
are forced to maintain expression of some non-(or less) vari-
able surface molecules in order to assimilate all the host factors 
they require for survival. A common architectural feature of try-
panosomes is the flagellar pocket (FP); an invagination of the 
membrane at the base of the flagellum. This structure is readily 
involved in exocytic and endocytic processes, cell division and 
polarity, protein trafficking and more importantly, virulence and 
immune evasion.38 Therefore, antigens present in the FP repre-
sent attractive candidates for vaccine development. A study from 
1995 showed that immunization of cattle with an apparently 
invariant antigen localized at the FP provided them with a par-
tial protection against infections, as reflected by the significant 
differences in disease incidence.39 A similar experiment was per-
formed in a murine model, where Balb/c susceptible mice were 
immunized with a FP preparation. A partial protection was also 
achieved in this case, since 60% of the mice survived the para-
site challenge. The 40% that succumbed to infection exhibited a 
doubled survival time and a delayed parasitemia onset. In spite of 
these ‘positive’ findings, subsequent challenges with higher para-
site load (inoculum of 103 parasites or more) demonstrated that 
the induced protection was temporary and only gave borderline 
immunity to low dose infection. Hence the authors proposed that 
FP vaccination was not the correct way forward.40
In a similar approach, targeting invariant trypanosome 
proteins, a number of molecular targets have been proposed, 
including the transferrin receptors ESAG6/7 and several invari-
ant surface glycoproteins (ISGs).41-44 According to recent data, 
vaccination with a DNA plasmid encoding a bloodstream-stage 
specific ISG enhances a partial protection of mice (40%),45 with 
surviving animals showing increased levels of IgG2a antibodies. 
However, in view of the earlier published anti-FP vaccinations 
it should be indicated that also here partial protection was only 
reported for a low-dose parasite challenge.
Other structural molecules that have been proposed as vac-
cination candidates are the subcellular proteins of the cytoskel-
eton i.e., actin and tubulin. The former has been shown to play ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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immunized and non-immunized controls. Nevertheless, immu-
nized cattle showed weight gain in posterior stages as well as less 
severe anemia. A role in immunosuppression was suggested for 
CP2, based on the more prominent IgG responses developed by 
cattle immunized against it, which mimics in a certain way the 
response of a trypanotolerant animal. Despite these promising 
results, there have been no further publications on the subject. A 
summary of the vaccine candidates presented above can be found 
in Table 1
The Main Pitfalls of Anti-trypanosome Vaccination: 
Antigenic Variation and Abrogation of B-cell 
Homeostasis and Memory
Despite all the anti-trypanosome trails reported and reviewed 
above, not a single ‘promising’ experimental result obtained in 
these studies has sparked off a positive field trial. Indeed, in real-
ity it appears that trypanosomes have evolved two defense mech-
anisms that protect them from antibody-mediated elimination 
by the immune system. The first mechanism involves the capac-
ity to modulate its own antigen ‘appearance’, while the second 
mechanism relies on undermining the hosts capacity to mount 
an efficient immune response and to maintain its immunological 
memory.
One of the most remarkable features of trypanosomes, as 
already mentioned above, is their ability to regularly switch their 
surface coat and hence evade immune destruction. This mecha-
nism is known as antigenic variation.68,69
Subsequent to the sequencing of the trypanosome genome, 
an enormous repertoire of VSG was identified, made up out of 
full-length VSG genes as well as a huge array of pseudogenes.70 
The latter coheres with the fact that many VSGs are expressed as 
mosaic products. In other words, the parasite greatly increases the 
variations of the expressed protein by creating a puzzle made of 
fragments of several genes. Trypanosomes exclusively express only 
one VSG out of that vast repertoire at the time. This, together with 
the fact that all T. brucei parasites survive extracellularly, would 
theoretically turn the parasite into an ‘easy target’ for antibody-
mediated killing by the host immune system. Even though the lat-
ter occurs upon infection, by the time the host mounts an efficient 
response against the most frequently encountered VSG, VSG 
switching has already taken place and a different VSG-expressing 
population has arisen. Hence, the mechanism of antigenic varia-
tion allows the parasites to continually escape the immune system 
of the host and in conclusion, it appears that even if many VSGs 
share combined epitopes, this molecule is unable to be targeted by 
an efficient destructive antibody response.
Taken the fact that many VSGs are expressed as mosaic pro-
teins of previously ‘used’ VSGs, it remains remarkable that this 
system of antigenic variation seems to be so effective in escaping 
immune recognition. The reason why this is the case, is most 
likely linked to the second defense system that trypanosomes 
have developed, i.e., the abrogation of B-cell homeostasis and 
the destruction of the host’s immunological memory. Together, 
these immune dysfunctions result in the lack of buildup of anti-
VSG memory, and hence allow the parasite to use over time 
developing an anti-disease vaccine, targeting infection-associated 
pathology rather than the parasite itself. One of the main targets 
in this approach is the glycosylphosphatidylinositol (GPI) anchor 
that attaches the VSG molecules to the parasite’s membrane. 
This anchor has been associated with the induction of TNFα 
activity. The relation between this cytokine and initiation of dis-
ease-associated immunopathology has long been recognized.54-56 
Upon environmental stress, trypanosomes can cleave their VSG 
anchor by means of a phospholipase hydrolytic enzyme,57 leav-
ing the dimyristoylglycerol (DMG) moiety attached to the 
membrane and releasing the glycosyl-inositol-phosphate (GIP) 
fragment.58 These two components of the GPI are able to elicit 
qualitatively different macrophage activations; the GIP (particu-
larly, the galactose chain within it) is responsible of the induction 
of TNFα production, whereas the DMG part primes the macro-
phages, thus becoming sensitized to other inflammatory agents 
such as LPS, and driving the induction of IL-1α secretion.59 In 
turn, IL-1α is implicated in TNFα production.60 Interestingly, 
serum levels of LPS have been reported to be increased during try-
panosome infection.61 Although the exact origin of the increased 
LPS levels remains to be elucidated, this makes the entire GPI-
macrophage priming physiologically relevant during disease 
development. Liposome-based GPI treatment of mice previous 
to parasitic challenge provoked a shift in the cytokine pattern 
observable during infection. In fact, it results in an increased 
expression of anti-inflammatory cytokine IL-10, whereas secre-
tion of pro-inflammatory mediators (TNF, IL-6 and IL-12) is 
impaired.62 This attenuation in inflammation enhanced a pro-
longed survival and alleviated the clinical symptoms of the infec-
tion (anemia, weight loss, liver damage, locomotor impairment), 
albeit it does not affect parasitemia development. In spite of these 
encouraging results and the presence of low but yet detectable 
antibodies against GPI, it was later demonstrated that the elic-
ited protection did not relate to the B cell compartment, since 
the positive outcome was exhibited in B-cell deficient animals 
as well. Hence, conventional B-cell memory involvement was 
thus precluded (unpublished data Magez S et al.). Interestingly 
a similar study was performed in the context of malaria infec-
tions by Schofield et al.63 This time, a synthetic molecule of GPI 
was utilized for immunization of mice. Resulting from its high 
immunogenicity, IgG antibodies could be detected in the sera. 
However, these antibodies were shown to be not only short-lived, 
but also dependent on the presence of parasite antigen.64 In this 
case, while the GPI vaccination did alleviate some of the inflam-
matory clinical symptoms, it did not result in prolongation of 
survival for the infected host.
A second approach in anti-disease vaccination for trypanoso-
miasis involves congopain, a cysteine protease (CP) that appears 
to elicit a high IgG response in trypanotolerant, though not 
in susceptible cattle. A role in pathogenicity was suggested for 
this molecule back in 1993.65 A first vaccination trial in cattle 
was reported in 2001.66 Here, trypanosusceptible animals were 
immunized with two predominant families of CPs (CP1 and 
CP2) that differ in their functional characteristics.67 Results 
from these experiments excluded any implication of CPs in early 
stages of infection, since no differences were observed between ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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of plasma cells grew smaller with time. Under no circumstances 
were germinal centers observed. As confirmed by Radwanska et 
al.77 not only is the architecture of the spleen severely affected 
by T. brucei infection, but the study of the cellular composi-
tion revealed a drastic disappearance of marginal zone B cells 
as well. This cell subset is the main mediator of T-cell indepen-
dent immune responses. Finally, the same authors showed that 
B-cell memory was gravely impaired, due to either depletion or 
hindered reactivation. Important to stress is that the destruc-
tion of the B-cell memory compartment appears to affect not 
only anti-trypanosome responses, but immunological memory 
in general. Indeed, using a combined model of DTPa vaccine 
(against diphtheria, tetanus and pertussis) and trypanosome 
challenges, Radwanska et al.77 showed that the latter destroys 
even unrelated vaccine induced memory responses such as the 
DTPa induced protection against a subsequent B. pertussis chal-
lenge. Using this knowledge, it was later shown that during 
experimental trypanosome infections in mice, exposure to a 
particular VSG does not provide the host with the capacity to 
mount a protective memory response against this given VSG. 
Indeed, re-challenge with a previously encountered trypano-
some stock is possible within weeks after encountering the same 
VSG antigenic variant.78
very similar VSG molecules, or even re-use a surface coat pro-
tein that already has been encountered by the host.
A number of studies reported four decades ago, already 
described the following key facts of T. brucei infection: (1) The 
immune system is unable to react against unrelated new anti-
gens upon infection;71 (2) there is a non-specific activation of 
immunoglobulin production;72 (3) the cellular components of 
the humoral response are no longer coordinated upon infec-
tion;73 (4) despite a sustained plasma cell hyperplasia, failure 
of antibody production (both IgM and IgG) at the cellular 
level occurs at 2–4 weeks post infection.74 Those findings were 
directly associated to the presence of living trypanosomes, since 
the immune competence was restored after treatment,75 and 
define the basis of immunosuppression, a hallmark of trypano-
some infections.
Further insight into B cell dysfunction was gained through 
the study of morphological and qualitative changes in secondary 
lymphoid organs.76 The first peak of parasitemia and a marked 
splenomegaly were observed simultaneously, the latter due to 
plasma cell proliferation in the white pulp and erythrocyte 
expansion in the red pulp of the spleen. These events were fol-
lowed by a gradual disorganization of the white pulp caused by 
the increasing number of red blood cells, whereas the amount 
Table 1. Summary of vaccine candidates reported in literature
Type of vaccine Antigen
Antigen 
preparation
Boosts
Time lapse last 
boost-challenge
Parasite load
Immunological 
outcome
Reference
intramuscular Fp
parasite  
isolated
3 14 d or more
Natural exposure 
in a field
partial  
protection
Mkunza et al. Vaccine 
199539
i.p. Fp
parasite  
isolated
3 Ni 500 x 103 partial/no  
protection
Radwanska et al. 
parasite immunol 
200040
i.p.
iSg65, 
iSg75
Recombinant 
protein
3 11 d 104 No protection
Ziegelbauer et al. J Biol 
chem 199344
i.p. iSg plasmid dNa 1 175 d 500
partial  
protection
Lança et al. exp parasitol 
201145
Subcutaneous actin
Recombinant 
protein
3 6 d 103 partial  
protection
Li et al. parasitol Res 
200947
Subcutaneous tubulin
Recombinant 
protein
3 6 d 103 partial  
protection
Li et al. parasite 
immunol 200748
Subcutaneous tubulin
parasite  
isolated
3 Ni 103 partial  
protection
Lubega et al. exp 
parasitol 200249
intramuscular Sialidase plasmid dNa 1 175 d 500
partial  
protection
Silva et al. parasitol Res 
200952
i.p.
cation 
atpases
Recombinant 
protein
3 6 weeks 106 No protection
Ramey et al. am J trop 
Med Hyg 200953
i.p. gpi Liposomes 2 3 weeks 5 x 103 partial  
protection
Stijlemans et al. J 
immunol 200762
Subcutaneous cp
Recombinant 
protein
4 1 mo
experimental 
tsetse fly  
challenge
partial  
protection
authie et al. int J 
parasitol 200166
i.p.: intraperitoneal; Fp: flagellar pocket; iSg: invariant surface glycoprotein; gpi: glycosylphosphatidylinositol; cp: cysteine protease; Ni: not indicated.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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human disease, due to the lack of means to analyze blood samples 
in the field and the presence of other infections or nutritional 
conditions.91 Consistent with previous data, a marked leucopenia 
could be observed in the animals around the same period when 
parasites could first be detected in peripheral blood. Strikingly, 
multiple peaks of white blood cell counts could be observed in 
subsequent days in all infected monkeys, suggesting that despite 
the immunosuppression described elsewhere for trypanosomia-
sis,72,73,75 some myeloid precursor cells are still able to prolifer-
ate in response to the multiple waves of parasitemia. Combined, 
these observations suggest that non-murine models might be a 
better way forward in future vaccine research, as they would cir-
cumvent intrinsic artifacts that are related to experimental try-
panosome infections in the mouse model.
Conclusion
Vaccination against trypanosomiasis should remain the ultimate 
goal in the fight against this disease, both in case of animal try-
panosomiasis and HAT. This assumption is based on two main 
observation: first, taken that it is an impossible task to eradicate 
the entire parasite reservoir of endemic areas, only vaccination 
will provide a long lasting economically viable option to prevent 
human casualties and vast economic losses due to livestock infec-
tions. Second, taken that trypanotolerance occurs in many mam-
mals endemic to regions where trypanosomiasis occurs, and that 
even in human infections immunological control of the infection 
has been reported, it appears that immune intervention to pre-
vent the deadly outcome of trypanosomiasis should be somehow 
a feasible target.
To date, not a single experimental anti-trypanosome vac-
cination protocol has made it to a stage where preliminary 
promising results have been reported in a field setting. One of 
the problems of experimental trypanosomiasis research might 
be the general use of murine models for basic research. While 
these models do serve their purpose in a certain context, it has 
become clear that with respect to B-cell function and memory 
maintenance during infection, mice suffer from trypanosomia-
sis-associated defects that might be specific for the model, and 
do not necessarily reflect the immunological situation of the 
natural host. Indeed, the fact that mice can be re-infected with 
previously encountered trypanosome variants suggest that anti-
genic variation only has a limited importance in the defense 
of the parasite against the destruction by the host (mouse) 
immune system. In contrast, the fact that trypanosomes very 
efficiently destroy vaccine induced immunological memory in a 
mouse setting, might be an exaggeration of what is observed in 
natural hosts, associated to the distorted parasite/immune cell 
ratio in mice, that exhibit abnormally high circulating para-
site numbers throughout infection. This last issue raises a very 
important question with respect to vaccine development and 
experimental vaccine trials: could it be that the murine model 
for trypanosomiasis is prone to failure when it comes to test-
ing the effect of B-cell immunity and B-cell memory? If so, it 
could be that many of the ‘failed’ murine vaccine studies using 
various conserved trypanosome surface molecules are actually 
Murine Model for African Trypanosomiasis: 
Introducing Artifacts or Providing Good Laboratory 
Working Models?
Despite the fact that the mouse model has been widely used 
in the study of African trypanosomiasis, the question remains 
whether it is indeed a valid model to study host-parasite interac-
tions and functional infection-associated immune alterations. 
However, the crucial contributions of the murine model to the 
understanding of trypanosomiasis can certainly not be denied. 
First, the use of inbred mouse strains has enabled the study of 
genetic determinants of susceptibility.79 Survival monitoring 
and the ability to control parasite load in homogeneous back-
grounds has enhanced the ranking of a wide range of strains 
from less to more susceptible to infection. Second, gene knock-
out technology has permitted the identification of key immune 
mediators during the infections, such as TNFα,27,80 IFNγ,81,82 
IL-10 83 or nitric oxide, and their relative importance accord-
ing to the species of the infecting trypanosome. In addition, 
mouse studies have provided valuable insight into a number 
of crucial aspects related to infection: the mechanism of anti-
genic variation,9,84 the B-cell compartment dysfunction77 as 
well as the impact of innate immunity on infection-associated 
complications.30,85
However, inbred mouse strains do not mimic a reality where the 
population at risk is undoubtedly heterogeneous. Furthermore, 
mice lack various host-specific interaction molecules such as 
for example the trypanolytic factors present in normal human 
serum. As a matter of fact, TLF activity is restricted to primates 
with the ApoL1.86 Finally, mice exhibit excessive parasitemia lev-
els as compared with natural hosts, drastically altering the ratio 
between the number of circulating parasites and immune cells. 
This ratio might greatly impact on the way the parasite deregu-
lates the immune system.
Models that circumvent the above-mentioned mouse arti-
facts do exist, but in turn bring their own issues and limitations. 
A number of studies performed on vervet monkeys have been 
described, offering a model of infection that is much closer to 
human infections.87-89 Working with non-human primates for 
infectious disease studies requires a unique infrastructure, and 
in terms of fundamental genetic approaches has huge limitations 
as compared with the mouse model. However, recently published 
data emphasize the advantage of the use of monkeys, whose infec-
tion accurately mimics that of humans.90 For example, infections 
started by a single tsetse fly bite showed different pre-patent peri-
ods in monkeys, consistent with the heterogeneity reported for 
HAT. Host factors are thus clearly involved in the outcome of the 
disease, beyond the intrinsic properties of the parasite that deter-
mine the virulence. Surprisingly, individuals with longer survival 
times showed more fluctuations in parasitemia levels. The simi-
larity of this animal model and the human disease has also per-
mitted some insight into the hematological consequences of the 
infection. For example, the anemia observed in vervet monkeys 
was of the microcytic hypochromic type, unlike the normocytic 
one usually reported in mice. Unfortunately, it is currently dif-
ficult to establish which of the two is most representative of the ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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finding a future anti-trypanosome vaccination approach, taken 
the very specific features of host-parasite interactions. 
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negatively biased by the intrinsic immune deficiency occur-
ring during trypanosome infections in mice. Possibly, using 
other, more relevant models for infection, could lead to other 
outcomes in vaccine trials. While there is no ‘easily accessible’ 
alternative for initial murine experiments, maybe such alterna-
tives have to be considered in order to increase the success of 
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